A recent work25 showed that tumours with co-occurring KRAS/P53 mutations were associated with higher PD-L1 expression as well as elevated PD-L1+/CD8+ cell ratio and increased mutation burden as compared to tumours with KRAS or P53 single mutation. This evidence concerns the gene KRAS and neoplasm.